Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: Status in a single center

Leukemia and Lymphoma

Volumn 52, Issue 4, 2011, Pages 597-603

  El Galaly, Tarec ^a   Prakash, Vineet ^a   Christiansen, Ilse ^a   Madsen, Jakob ^a   Johansen, Preben ^a   Boegsted, Martin ^a   Johnsen, Hans Erik ^a   Bukh, Anne ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

cost effectiveness; follow up; Non Hodgkin lymphoma; PET CT; positron emission tomography; relapse

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79953214094     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.547642     Document Type: Article

References (33)

1. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636. (Pubitemid 19272832)
2. Torrey MJ, Poen JC, Hoppe RT. Detection ofrelapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 1997;15:1123-1130. (Pubitemid 27106298)
3. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991;9:1196-1203.
4. Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ 1997;314:343-346. (Pubitemid 27056556)
5. Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44: 123-125. (Pubitemid 36113838)
6. Dryver ET, Jernström H, Tompkins K, Buckstein R, Imrie KR. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is oflittle value. Br J Cancer 2003;89:482-486. (Pubitemid 37026429)
7. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006;17:909-913. (Pubitemid 43778979)
8. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost-effectiveness analysis of computerized tomography in the routine follow-up ofpatients after primary treatment for Hodgkin's disease. J Clin Oncol 2006;24:4116-4122. (Pubitemid 46622287)
9. de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997;8(Suppl. 1):s57-s60. (Pubitemid 27239431)
10. Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000; 11(Suppl. 1):147-150.
11. Cherry SR. The 2006 Henry N. Wagner Lecture: Ofmice and men (and positrons)-advances in PET imaging technology. J Nucl Med 2006;47:1735-1745. (Pubitemid 47545014)
12. Allen-Auerbach M, Quon A, Weber WA, et al. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004;6:411-416. (Pubitemid 39618921)
13. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-1209. (Pubitemid 39655178)
14. Hutchings M, Specht L. PET/CT in the management of haematological malignancies. Eur J Haematol 2008;80:369-380. (Pubitemid 351503112)
15. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
16. DRG tariffs from Ministry of Interior and Health, Denmark [Internet] [cited 15 May 2010]. Available from: im.dk/Sundhed/DRG-systemet/Takster/2010. aspx
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253. (Pubitemid 29162950)
18. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment ofaggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000;39:543-553. (Pubitemid 32162393)
19. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) afterfirst-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-419. (Pubitemid 32112853)
20. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by inte-grated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652-4661. (Pubitemid 46224067)
21. Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 2006;28:711-714. (Pubitemid 44786433)
22. Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2006;28: 300-306.
23. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-130. (Pubitemid 36150270)
24. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluor-odeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781-1787.
25. Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer 2010;116: 3835-3842.
26. Jatoi I, Zhu K, Shah M, Lawrence W. Psychological distress in U.S. women who have experienced false-positive mammo-grams. Breast Cancer Res Treat 2006;100:191-200. (Pubitemid 44631921)
27. Katz DA, Jarrard DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG. Health perceptions in patients who undergo scre-ening and workup for prostate cancer. Urology 2007;69:215-220. (Pubitemid 46274922)
28. Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009;251:166-174.
29. Tubiana M, Feinendegen LE, Yang C, Kaminski JM. The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. Radiology 2009;251:13-22.
30. Nakamoto Y, Nogami M, Sugihara R, Sugimura K, Senda M, Togashi K. Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/com-puted tomography? Ann Nucl Med 2010 Oct 19. [Epub ahead of print].
31. Petrausch U, Samaras P, Veit-Haibach P, et al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 2010;21:1053-1057.
32. Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol 2010 Aug 13. [Epub ahead of print].
33. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102: 1989-1996. (Pubitemid 37122371)